We found that TP53 mutation status was not significantly associated with NSCLC stage at diagnosis (p = 0.21, χ2 test) (Fig. 1E), but was significantly associated with reduced overall survival in patients diagnosed with stage I-III NSCLC (Fig. 1F and Supplementary Fig. 2; HR = 1.97, HR 95% CI 1.45–2.66, p < 1e-04, Wald’s test). This evidence concerns the gene TP53 and non-small cell lung carcinoma.